

## Insulin Glargine Formulation

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
Date of first issue: 01/07/2015

---

### SECTION 1. IDENTIFICATION

Product name : Insulin Glargine Formulation

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Skin irritation : Category 2  
Serious eye damage : Category 1  
Specific target organ toxicity : Category 2 (Blood, Nervous system)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.  
H315 Causes skin irritation.  
H318 Causes serious eye damage.  
H373 May cause damage to organs (Blood, Nervous system) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**  
P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P280 Wear protective gloves, eye protection and face protection.

---

## Insulin Glargine Formulation

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
 Date of first issue: 01/07/2015

### Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.  
 P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER.

P314 Get medical attention if you feel unwell.

P332 + P313 If skin irritation occurs: Get medical attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

### Other hazards

None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Insulin Glargine	160337-95-1	>= 90 - <= 100
m-Cresol	108-39-4	>= 1 - < 5

Actual concentration is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
 If easy to do, remove contact lens, if worn.  
 Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes skin irritation.  
 Causes serious eye damage.  
 May cause damage to organs through prolonged or repeated

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/19/2022
9.9	10/01/2022	42894-00026	Date of first issue: 01/07/2015

---

Protection of first-aiders : exposure if swallowed.  
 : First Aid responders should pay attention to self-protection,  
 and use the recommended personal protective equipment  
 when the potential for exposure exists (see section 8).  
 Notes to physician : Treat symptomatically and supportively.

---

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical  
 Unsuitable extinguishing media : None known.  
 Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
 Exposure to combustion products may be a hazard to health.  
 Hazardous combustion products : Carbon oxides  
 Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.  
 Evacuate area.  
 Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
 Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
 Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).  
 Environmental precautions : Avoid release to the environment.  
 Prevent further leakage or spillage if safe to do so.  
 Retain and dispose of contaminated wash water.  
 Local authorities should be advised if significant spillages cannot be contained.  
 Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
 Sections 13 and 15 of this SDS provide information regarding

## Insulin Glargine Formulation

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
 Date of first issue: 01/07/2015

certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
 Do not breathe dust.  
 Do not swallow.  
 Do not get in eyes.  
 Wash skin thoroughly after handling.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Insulin Glargine	160337-95-1	TWA	3 µg/m <sup>3</sup> (OEB 4)	Internal
m-Cresol	108-39-4	TWA	2.3 ppm 10 mg/m <sup>3</sup>	NIOSH REL
		TWA	5 ppm 22 mg/m <sup>3</sup>	OSHA Z-1
		TWA (Inhalable fraction and vapor)	20 mg/m <sup>3</sup>	ACGIH

- Engineering measures** : Ensure adequate ventilation, especially in confined areas.  
 Minimize workplace exposure concentrations.  
 Apply measures to prevent dust explosions.  
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

## Insulin Glargine Formulation

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
Date of first issue: 01/07/2015

---

### Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
- Eye protection : Wear the following personal protective equipment:  
Chemical resistant goggles must be worn.  
If splashes are likely to occur, wear:  
Face-shield
- Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.  
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.
- 

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : Crystalline powder
- Color : white
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available

**Insulin Glargine Formulation**

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
Date of first issue: 01/07/2015

---

Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents

## Insulin Glargine Formulation

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
Date of first issue: 01/07/2015

---

Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: 3,025 mg/kg  
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

#### Components:

##### **Insulin Glargine:**

Acute oral toxicity : Remarks: No data available

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

##### **m-Cresol:**

Acute oral toxicity : LD50 (Rat): 121 mg/kg  
Remarks: Based on data from similar materials

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Acute dermal toxicity : LD50 (Rabbit): 301 mg/kg  
Remarks: Based on data from similar materials

#### **Skin corrosion/irritation**

Causes skin irritation.

#### Components:

##### **Insulin Glargine:**

Remarks : No data available

##### **m-Cresol:**

Species : Rabbit

Result : Corrosive after 3 minutes to 1 hour of exposure

## Insulin Glargine Formulation

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
Date of first issue: 01/07/2015

---

### Serious eye damage/eye irritation

Causes serious eye damage.

#### Components:

##### Insulin Glargine:

Remarks : No data available

##### m-Cresol:

Species : Rabbit  
Result : Irreversible effects on the eye

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

#### Respiratory sensitization

Not classified based on available information.

#### Components:

##### Insulin Glargine:

Remarks : No data available

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Insulin Glargine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Result: negative  
Remarks: Based on data from similar materials

##### m-Cresol:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)



## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/19/2022
9.9	10/01/2022	42894-00026	Date of first issue: 01/07/2015

---

Species: Mouse  
 Application Route: Ingestion  
 Method: OECD Test Guideline 475  
 Result: negative

### Carcinogenicity

Not classified based on available information.

#### Components:

##### Insulin Glargine:

Species : Rat  
 Exposure time : 2 Years  
 NOAEL : 0.455 mg/kg body weight  
 Result : negative

Species : Mouse  
 Exposure time : 2 Years  
 NOAEL : 0.455 mg/kg body weight  
 Result : negative

##### m-Cresol:

Species : Mouse, males  
 Application Route : Ingestion  
 Exposure time : 105 weeks  
 Result : equivocal  
 Remarks : Based on data from similar materials

Species : Mouse, female  
 Application Route : Ingestion  
 Exposure time : 106 - 107 weeks  
 Result : positive  
 Remarks : Based on data from similar materials

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity

Not classified based on available information.

#### Components:

##### Insulin Glargine:

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/19/2022
9.9	10/01/2022	42894-00026	Date of first issue: 01/07/2015

---

Application Route: Subcutaneous  
 Fertility: NOAEL: 0.36 mg/kg body weight  
 Result: No effects on fertility.

Test Type: Fertility/early embryonic development  
 Species: Rabbit  
 Application Route: Subcutaneous  
 Fertility: NOAEL: 0.072 mg/kg body weight  
 Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat  
 Application Route: Subcutaneous  
 Developmental Toxicity: NOAEL: 0.36 mg/kg body weight  
 Result: No effects on fetal development.

Species: Rabbit  
 Application Route: Subcutaneous  
 Developmental Toxicity: LOAEL: 0.072 mg/kg body weight  
 Result: Fetotoxicity.  
 Remarks: The mechanism or mode of action may not be relevant in humans.

### **m-Cresol:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on fetal development : Test Type: Prenatal development toxicity study (teratogenicity)  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

### **STOT-single exposure**

Not classified based on available information.

### **STOT-repeated exposure**

May cause damage to organs (Blood, Nervous system) through prolonged or repeated exposure if swallowed.

### **Components:**

#### **Insulin Glargine:**

Routes of exposure : Ingestion  
 Target Organs : Blood, Nervous system  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

## Insulin Glargine Formulation

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
 Date of first issue: 01/07/2015

---

### Repeated dose toxicity

#### Components:

##### Insulin Glargine:

Species : Rat  
 NOAEL : 0.5 mg/kg  
 LOAEL : 1.5 mg/kg  
 Application Route : Subcutaneous  
 Exposure time : 30 d  
 Target Organs : Blood, Nervous system

##### m-Cresol:

Species : Rat  
 NOAEL : 150 mg/kg  
 Application Route : Ingestion  
 Exposure time : 13 Weeks  
 Method : OECD Test Guideline 408

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### Insulin Glargine:

Inhalation : Target Organs: Blood  
 Symptoms: Hypoglycemia, Headache, Sweating, Tremors, Nausea

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### m-Cresol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 8.6 mg/l  
 Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia pulex (Water flea)): > 99.5 mg/l  
 Exposure time: 48 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1.35 mg/l  
 Exposure time: 32 d  
 Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1 mg/l  
 Exposure time: 21 d  
 Remarks: Based on data from similar materials

## Insulin Glargine Formulation

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
Date of first issue: 01/07/2015

---

### Persistence and degradability

#### Components:

##### **m-Cresol:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 90 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301D

### Bioaccumulative potential

#### Components:

##### **m-Cresol:**

Bioaccumulation : Species: Leuciscus idus (Golden orfe)  
Bioconcentration factor (BCF): 17 - 20

Partition coefficient: n-octanol/water : log Pow: 1.96

#### **Mobility in soil**

No data available

#### **Other adverse effects**

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### **International Regulations**

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

### **Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

### **Domestic regulation**

#### **49 CFR**

UN/ID/NA number : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

---

## Insulin Glargine Formulation

Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
Date of first issue: 01/07/2015

(m-Cresol)

Class : 9  
Packing group : III  
Labels : CLASS 9  
ERG Code : 171  
Marine pollutant : no  
Remarks : THE ABOVE INFORMATION ONLY APPLIES TO PACKAGE SIZES WHERE THE HAZARDOUS SUBSTANCE MEETS THE REPORTABLE QUANTITY.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

Components	CAS-No.	Component RQ (lbs)	Calculated product RQ (lbs)
m-Cresol	108-39-4	100	2500

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Combustible dust  
Specific target organ toxicity (single or repeated exposure)  
Skin corrosion or irritation  
Serious eye damage or eye irritation

**SARA 313** : The following components are subject to reporting levels established by SARA Title III, Section 313:

m-Cresol                      108-39-4                      >= 1 - < 5 %

**US State Regulations****Pennsylvania Right To Know**

Insulin Glargine                      160337-95-1  
m-Cresol                                      108-39-4

**California List of Hazardous Substances**

m-Cresol                                      108-39-4

**California Permissible Exposure Limits for Chemical Contaminants**

m-Cresol                                      108-39-4

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

## Insulin Glargine Formulation


Version 9.9      Revision Date: 10/01/2022      SDS Number: 42894-00026      Date of last issue: 05/19/2022  
 Date of first issue: 01/07/2015

IECSC : not determined

### SECTION 16. OTHER INFORMATION

#### Further information

##### NFPA 704:



##### HMIS® IV:

<b>HEALTH</b>	*	<b>3</b>
<b>FLAMMABILITY</b>		<b>3</b>
<b>PHYSICAL HAZARD</b>		<b>0</b>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 NIOSH REL : USA. NIOSH Recommended Exposure Limits  
 OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants  
 ACGIH / TWA : 8-hour, time-weighted average  
 NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek  
 OSHA Z-1 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/19/2022
9.9	10/01/2022	42894-00026	Date of first issue: 01/07/2015

---

50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 10/01/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8